Therapeutics News and Research

RSS

Cytori Therapeutics announces independent clinical study results in breast reconstruction presented at the Association of Breast Surgery conference

Cytori Therapeutics, Inc. (NASDAQ: CYTX) reports that surgeons from North Tees and Hartlepool NHS Foundation Trust have presented clinical outcomes using Adipose-Derived Regenerative Cell (ADRC) fat grafting in reconstructive breast surgery at the Association of Breast Surgery Conference in Manchester, UK, May 16-17, 2011. The procedure, referred to by Cytori as RESTORE, was separately investigated in Cytori’s own RESTORE 2 trial.

17 May 2011

ProBioGen, Life Technologies' new cell line development kits now available for biologic drug production

Life Technologies Corporation and ProBioGen AG today announced the availability of Gibco Freedom Cell Line Development Kits, a new line of royalty-free products that integrate cells, reagents, culture media and protocols to bring simplicity and flexibility, eliminating up to two months in the earliest stages of new biological drug development.

17 May 2011

Benitec raises AU$8 million for gene silencing therapeutics

Benitec Ltd (ASX:BLT), a world leader in RNA-based gene silencing for human therapeutics, today announced its fully underwritten AU$8 million renounceable rights issue, incorporating an entitlement offer and a shortfall offer, had successfully closed oversubscribed.

17 May 2011

InVivo Therapeutics reports net loss of $1,278,000 for first quarter 2011

InVivo Therapeutics, a medical device company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries, today reported financial results for the first quarter 2011.

16 May 2011

Techulon receives U.S. patent protection for Glycofect Discovery and Therapeutic Delivery Platform

Techulon, Inc. announced today that its Glycofect Discovery and Therapeutic Delivery Platform has been awarded United States patent protection. The patented invention provides a new class of non-viral transfection vectors based on synthetic carbohydrate containing polyamides that can be used for both in vivo and in vitro applications.

16 May 2011

Nuvo Research acquires ZARS Pharma

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products primarily for the treatment of pain, today announced that it has completed its acquisition of ZARS Pharma, Inc.

13 May 2011

Pro-Pharmaceuticals reports net loss of $2.7 million for first quarter 2011

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the first quarter, ended March 31, 2011.

13 May 2011

Maximum chest compression during chiropractic manipulation is unlikely to result in injury

Dynamic chest compression occurs during spinal manipulation. While dynamic chest compression has been well studied in events such as motor vehicle collisions, chest compression forces have not been studied during chiropractic manipulation.

13 May 2011

ETI finalizes proprietary progesterone formulations for Traumatic Brain Injury

Encore Therapeutics, Inc. today reported finalizing its proprietary phospholipid nanoemulsion formulation of progesterone.

12 May 2011

Trillium raises $1 million to advance TTI-1612 into clinical trials for interstitial cystitis treatment

Trillium Therapeutics Inc., a privately-held biopharmaceutical company, announced today that it has raised $1 million from a new undisclosed investor. The funds will be used to advance its lead program, TTI-1612, into clinical trials for the treatment of interstitial cystitis, also known as bladder pain syndrome. The first trial is projected to start in the second half of this year.

12 May 2011

Cell Biosciences announces acquisition of Brightwell Technologies

Cell Biosciences, Inc. today announced that it has acquired Brightwell Technologies, Inc. of Ottawa, Ontario for approximately U.S. $9 million in cash.

12 May 2011

CrystalGenomics receives draft CSR for CG400549 Phase I MAD study in Staph infections

CrystalGenomics, Inc., a biopharmaceutical company with 3 clinical stage candidates, has announced today that the draft Clinical Study Report from CG400549's Phase I Multiple Ascending Dose Study has just been received.

12 May 2011

Conference to discuss process of synaptic plasticity in Alzheimer's disease

Optimal functioning of neural networks is critical to the complex cognitive processes of memory, language, emotion and reasoning that deteriorate in people suffering from Alzheimer's disease.

12 May 2011

Tosedostat and OPAXIO study results to be presented at ASCO Annual Meeting

Cell Therapeutics, Inc. announced that data from a study with OPAXIO, in patients with newly diagnosed high-grade gliomas, and interim results from a study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia, will be presented at the 2011 American Society of Clinical Oncology Annual Meeting, which will be held June 3-7, 2011, in Chicago, Illinois. Both studies were selected for oral poster discussion sessions.

12 May 2011

BWH Karp Laboratory acquires BioFlux 1000 system for stem cell homing research

Fluxion Biosciences announced today that the Karp Laboratory at the Brigham and Women's Hospital (BWH) has purchased the BioFlux 1000 system, which will be applied in their stem cell homing research.

From Fluxion Biosciences 12 May 2011

FDA accepts Insys NDA for Fentanyl SL Spray to treat breakthrough cancer pain

Insys Therapeutics, Inc. today announced that the Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for Fentanyl SL Spray. The FDA will notify Insys of its PDUFA date in the 74-day letter which is expected in the upcoming weeks.

12 May 2011

ViroPharma, Halozyme sign license deal to develop Cinryze against hereditary angioedema

Halozyme Therapeutics, Inc. and ViroPharma Incorporated, today announced the signing of a worldwide exclusive licensing agreement for the use of rHuPH20 in the development of a subcutaneous formulation of Cinryze .

12 May 2011

Symphogen to present second-generation Sympress platform at ESACT conference

Symphogen, a private biopharmaceutical company developing superior antibody therapeutics to treat cancer, infectious and autoimmune diseases, announced today that second-generation enhancements to the company's SYMPRESS manufacturing and quality control platform will be presented in an oral presentation entitled "Recombinant antibody mixtures; optimization of cell line generation and single-batch manufacturing processes" by Dr. Søren K. Rasmussen, Principal Scientist, Symphogen at the upcoming European Society for Animal Cell Technology conference in Vienna on May 17, 2011.

11 May 2011

Pacira Pharmaceuticals reports net loss of $9.8 million for first quarter 2011

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced financial results for the first quarter ended March 31, 2011, provided an update on the execution of its pre-commercial and launch strategies for EXPAREL, and reiterated 2011 financial guidance.

11 May 2011

GATTEX Phase 3 study results in adult short bowel syndrome presented at DDW 2011

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced that GATTEX, a novel, recombinant analog of human glucagon-like peptide 2, was found to effectively and safely reduce parenteral support volume in adult short bowel syndrome-intestinal failure patients.

11 May 2011

Therapeutics News and Research

Cytori Therapeutics announces independent clinical study results in breast reconstruction presented at the Association of Breast Surgery conference

ProBioGen, Life Technologies' new cell line development kits now available for biologic drug production

Benitec raises AU$8 million for gene silencing therapeutics

InVivo Therapeutics reports net loss of $1,278,000 for first quarter 2011

Techulon receives U.S. patent protection for Glycofect Discovery and Therapeutic Delivery Platform

Nuvo Research acquires ZARS Pharma

Pro-Pharmaceuticals reports net loss of $2.7 million for first quarter 2011

Maximum chest compression during chiropractic manipulation is unlikely to result in injury

ETI finalizes proprietary progesterone formulations for Traumatic Brain Injury

Trillium raises $1 million to advance TTI-1612 into clinical trials for interstitial cystitis treatment

Cell Biosciences announces acquisition of Brightwell Technologies

CrystalGenomics receives draft CSR for CG400549 Phase I MAD study in Staph infections

Conference to discuss process of synaptic plasticity in Alzheimer's disease

Tosedostat and OPAXIO study results to be presented at ASCO Annual Meeting

BWH Karp Laboratory acquires BioFlux 1000 system for stem cell homing research

FDA accepts Insys NDA for Fentanyl SL Spray to treat breakthrough cancer pain

ViroPharma, Halozyme sign license deal to develop Cinryze against hereditary angioedema

Symphogen to present second-generation Sympress platform at ESACT conference

Pacira Pharmaceuticals reports net loss of $9.8 million for first quarter 2011

GATTEX Phase 3 study results in adult short bowel syndrome presented at DDW 2011

Next-generation therapeutics eBook eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News